pleurocidin

09/01/2011 - "Our results indicate that specific pleurocidin variants are attractive cancer-selective agents that selectively induce cell death in target cells but leave non-target cells such as erythrocytes and non-transformed cells unaffected."
07/17/2021 - "There is promising evidence for pleurocidin as a novel anti-cancer therapy. "
07/17/2021 - "Research efforts focused on pleurocidin may result in novel treatment strategies against antibiotic-resistant bacteria and cancer. "
10/19/2023 - "We examined toxicity against cancer cell lines and antibacterial activities of the pleurocidin-like AMP NRC-07 upon encapsulation in CS-NPs by ionotropic gelation. "
01/01/2022 - "Pleurocidin-family cationic antimicrobial peptide NRC-03 exhibits potent and selective cytotoxicity towards cancer cells. "

11/27/2020 - "Here we describe modification strategies that generate pleurocidin analogues with substantially improved, broad spectrum, antibacterial properties, which are effective in murine models of bacterial lung infection. "
02/01/2019 - "Taken together, the results suggested that pleurocidin is a promising candidate therapeutic agent to treat drug-resistant bacteria and biofilm-related infections."

10/24/2011 - "The purpose of this investigation was to determine the effect of the pleurocidin-family CAPs, NRC-03 and NRC-07, on breast cancer cells. "
12/01/2015 - "We previously reported that the pleurocidin NRC-03 causes lysis of breast cancer and multiple myeloma cells. "
12/01/2015 - "Enhanced killing of breast cancer cells by a d-amino acid analog of the winter flounder-derived pleurocidin NRC-03."
10/01/2013 - "The aim of this study was to determine whether human and mouse multiple myeloma cells are killed by the pleurocidin-like cationic antimicrobial peptides NRC-03 and NRC-07, previously shown to be active against breast cancer cells. "
01/01/2020 - "MDA-MB-231 Breast Cancer Cells Resistant to Pleurocidin-Family Lytic Peptides Are Chemosensitive and Exhibit Reduced Tumor-Forming Capacity."

12/01/2015 - "We previously reported that the pleurocidin NRC-03 causes lysis of breast cancer and multiple myeloma cells. "
10/01/2013 - "Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts."
10/01/2013 - "The aim of this study was to determine whether human and mouse multiple myeloma cells are killed by the pleurocidin-like cationic antimicrobial peptides NRC-03 and NRC-07, previously shown to be active against breast cancer cells. "

11/21/2023 - "Fibrous matrices facilitate pleurocidin killing of wound associated bacterial pathogens."
11/21/2023 - "Taken together, we show that electrospun, pleurocidin-loaded wound matrices have potential to be investigated for wound infection treatment."
11/21/2023 - "Wound matrices are often applied in parallel or sequentially with the use of standard wound care with biocides, therefore the presence and effect of biocides on pleurocidin potency was tested. "
11/21/2023 - "Here we describe an electrospun carrier system for topical application of pleurocidin, demonstrating sufficient AMP release from matrices to kill wound-associated pathogens including Acinetobacter baumannii and Pseudomonas aeruginosa. "
11/21/2023 - "Pleurocidin can be incorporated into polyvinyl alcohol (PVA) fiber matrices, using coaxial electrospinning, without major drug loss with a peptide content of 0.7% w/w predicted sufficient to kill most wound associated species. "